"Today, Maryland Oncology Hematology is the largest independent Medical Oncology and Hematology group in Maryland with 30 physicians practicing in 9 locations across central Maryland. Dedicated to providing the most advanced cancer care available anywhere in an atmosphere of caring compassion."

During the past decade, Maryland Oncology Hematology conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 1 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Maryland Oncology Hematology" #1 sponsor was "Gilead Sciences" with 2 trials, followed by "Agendia" with 1 trials sponsored, "Astellas Pharma Global Development, Inc." with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored and "Calithera Biosciences, Inc" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Maryland Oncology Hematology" #1 collaborator was "Genentech, Inc." with 1 trials as a collaborator and "Hoffmann-La Roche" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Maryland Oncology Hematology" are "Breast Cancer" (2 trials), "Cancer" (1 trials), "KEAP1 Gene Mutation" (1 trials), "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer" (1 trials) and "Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer" (1 trials). Many other conditions were trialed in "Maryland Oncology Hematology" in a lesser frequency.

Most popular intervention types in "Maryland Oncology Hematology" are "Drug" (5 trials), "Biological" (1 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Gemcitabine" (2 trials), "Placebo" (2 trials), "Atezolizumab" (1 trials), "Avelumab" (1 trials) and "Capecitabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Maryland Oncology Hematology" are 7 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Maryland Oncology Hematology". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Maryland Oncology Hematology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Maryland Oncology Hematology, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".